Occasional patients with chronic sinusitis who use intranasal ... He has been a practicing physician for 30 years. Ransom JH. Sinusitis: Diagnosis and Treatment. MedGenMed 1(1), 1999 [formerly ...

The global sinus therapeutic drugs market is experiencing robust growth, with projections indicating it will reach USD 6.35 billion by 2032, according to the latest analysis by Future Market Insights ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

We are pleased to have fully enrolled the second of our two pivotal trials of LYR-210 in CRS patients, and our team is moving forward expeditiously to report the results in Q2 of next year,” said ...

The overall incidence and severity of treatment-emergent adverse events ... nasal polyp growth and nasal obstruction.” CRSwNP is a chronic condition that affects up to 4% of the general ...

A BUNGED up nose is one of the many joys cold and flu season brings each year. Though having to dab at your streaming schnoz with tissues can be a real headache, most of us tend to assume that ...

The diagnosis of chronic sinusitis is made when the ... He has been a practicing physician for 30 years. Ransom JH. Sinusitis: Diagnosis and Treatment. MedGenMed 1(1), 1999 [formerly published ...

GSK said its depemokimab respiratory drug met the main objectives in two late-stage clinical trials, showing efficacy for the treatment of chronic rhinosinusitis with nasal polyps.